.png)
Company Overview
Suven Life Sciences Limited (Suven) is an Indian biopharmaceutical company focused on drug discovery and development of New Chemical Entities (NCEs) for disorders of the Central Nervous System (CNS), particularly areas involving unmet medical needs. The company was incorporated in 1989 as Suven Pharmaceuticals Private Limited and was converted into a public limited company in January 1995. Its name was changed to Suven Life Sciences Limited in 2003. The company's shares are listed on the BSE Limited and National Stock Exchange of India Limited.
Suven's registered office and head office are in Hyderabad, Telangana, India. The company's official locations page identifies its head office at SDE Serene Chambers, Banjara Hills, Hyderabad, and operating locations in Hyderabad and Sangareddy.
Business and Industry
Suven operates in the biopharmaceutical and pharmaceutical research industry. Following the demerger of its Contract Research and Manufacturing Services (CRAMS) business, sanctioned by the National Company Law Tribunal in January 2020, the company has focused on its drug-discovery and development activities. The CRAMS undertaking, including associated assets, licences, approvals and employees, was transferred to the resulting company, Suven Pharmaceuticals Limited.
The company's current principal activity is the discovery and development of proprietary NCEs targeting CNS disorders. Its research programs encompass areas such as neurological and psychiatric disorders. The company describes its objective as developing treatments for unmet medical needs in mental health and pursuing new CNS therapies.
Research and Development
Research and development is central to Suven's operating model. The company develops internally discovered molecules through preclinical and clinical development programs and seeks to advance candidates through the pharmaceutical development process. Its FY2024–25 annual report states that the company had 13 molecules in its pipeline, including five molecules in clinical trials, with three in Phase 2 and Phase 3 stages. The same report states that Suven had more than 2,850 global patents expiring in 2035 and beyond and employed 132 people, including 102 research scientists, as of the report's publication.
For FY2024–25, the company reported expenditure of approximately ₹304.3 crore on research and development of drug-discovery molecules. Its annual report states that standalone and consolidated revenue from operations for the year was ₹6.66 crore, while the consolidated loss was principally associated with clinical-development expenditure incurred by its wholly owned U.S. subsidiary.
Drug Discovery and Development Services
In addition to proprietary drug-development programs, Suven's official website describes Drug Discovery & Development Support Services (DDDSS) provided to global pharmaceutical and biotechnology companies. These services include synthetic and medicinal chemistry, analytical chemistry, in-vitro biology, ADME studies, in-vivo pharmacokinetics, pharmacology, toxicology, bioanalysis and NCE formulation.
These capabilities support activities including preclinical candidate selection, pharmacokinetic assessment and drug-product development. The company's customer base for these services therefore includes global pharmaceutical and biotechnology companies.
Vision and Mission
Suven's officially published vision and mission framework focuses on becoming a leading company developing treatments for unmet medical needs in mental health, providing health benefits for patients and value for partners, and pursuing new therapies for CNS disorders.
A separate, formally published current list of corporate core values was not identified in the official materials reviewed. Information not officially disclosed.
Subsidiary and Geographic Presence
The FY2024–25 annual report identifies Suven Neurosciences Inc., a Delaware, USA company, as a wholly owned subsidiary. The subsidiary is involved in the clinical development of Suven's NCE molecules. The annual report states that Suven had invested approximately US$94.74 million in the subsidiary as of June 2025 for clinical development activities.
Suven's research and development activities and corporate operations are centered in India, while its clinical-development activities and subsidiary operations extend to the United States. Its NCE development programs are intended for global markets.
Certifications, Patents and Recognitions
Suven's official history records certifications including ISO 9001, ISO 14001 and OHSAS 18001, as well as acceptance of its manufacturing facilities by the U.S. Food and Drug Administration during its earlier pharmaceutical operations.
The company has also received several officially recorded recognitions, including Pharmexcil Gold and Platinum Patent Awards, the Bio-Excellence Award, Star Export House recognition from the Ministry of Commerce and Industry, and Forbes Asia's Best Under a Billion Award (2014).
Official References
Source note: This biography has been prepared using information published on Suven Life Sciences Limited's official website, official annual reports and official corporate disclosures. No blogs, forums, third-party company profiles or unverified sources have been used.
.png)